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We report the induction of apoptosis in a human neuroblastoma cell line SK-N-BE(2) by cisplatm or retinoic acid, and its relation to cell cycle. 
Apoptosis was monitored by countmg apoptotic bodies and evaluating the activity of ‘tissue’ transglutaminase (EC 2.3.2.13), one of the genes 
specifically expressed in apoptotic cells. Data indicate that both agents enhance apoptosis, even though cells arrest at different cell cycle phases. 
In fact, retinoic acid causes accumulatron in G,, whilst cisplatin induces accumulation of cells in the GJM phase. This evidence suggests the presence 
of multiple start points for the apoptotic death programme withm the cell cycle of human neuroblastoma cells. 
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1. INTRODUCTION 
Apoptosis is the genetically controlled process lead- 
ing to cell self-elimination in tissues [11,30,31]. It also 
plays a pivotal role in the control of tumour cell prolif- 
eration by counterbalancing the effect of mitosis, hence 
regulating cell number [11,30.31]. Apoptosis occurs in 
isolated cells featuring compaction of the cytoplasm and 
organelles, smoothing of the plasma membrane, and the 
presence of condensed chromatin in characteristic ar- 
rays which correspond at the molecular level to its 
cleavage at internucleosomal sites, thus causing the 
characteristic DNA ladder [11,30,31]. This DNA frag- 
mentation is allegedly due to the activation of a yet 
uncharacterized Ca”-Mg”-dependent endonuclease 
[30,31]. The molecular mechanisms regulating the apop- 
totic program have not been fully elucidated as yet; 
however, under physiological conditions, its require- 
ment for RNA and protein synthesis indicates the con- 
trol by specific genes [l 11. We reported the specific ex- 
pression of ‘tissue’ transglutaminase (tTG) in several 
cell types undergoing the apoptotic program including 
human neuroblastoma cells [ 11.12,2&26,29]. Transglu- 
taminases (EC 2.3.2.13) are Ca”-dependent enzymes 
catalyzing cross-linking reactions among polypeptide 
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chains, leading to the formation of protein polymers 
insoluble in detergents and chaotropic agents [13]. In- 
deed, tTG activation results in the assembly of a highly 
cross-linked protein scaffold which temporarily stabi- 
lizes the integrity of the dying cell before its clearance 
by phagocytosis or shedding into body cavities [11,12]. 
Neuroblastomas in culture are characterized by the 
presence of three morphologically and biochemically 
distinct phenotypes (i.e. neural ‘N-type’, intermediate 
‘I-type’, and flat substrate-adherent ‘S-type’) which un- 
dergo transdifferentiation [4,20]. Human neuroblas- 
toma SK-N-BE(2) cells differentiate toward a neural 
phenotype upon retinoic acid (RA) treatment [15,19- 
2 1,24,26]. Moreover, we recently demonstrated that 
during the RA-treatment, a subset (S-type) of SK-N- 
BE(2) cells undergo apoptosis; the latter specifically ex- 
press high tTG protein level [20,24,26]. It has recently 
been suggested that anticancer drugs exert their biolog- 
ical effects by triggering cell death by apoptosis 
[1,5,7,17,28]. The possibility to evoke a specific cell 
death pathway in cancer cells has obvious therapeutic 
importance. The aim of this study was to investigate the 
effect of cisplatin and RA on apoptosis in human neu- 
roblastoma cells in relation to the cell cycle. 
2. MATERIALS AND METHODS 
1.1. C%emicals 
[1,4(n)-‘H]Putrescine dihydrochloride (26.3 Ci/mmol) was from 
Amersham, Bucks, UK). Optifluor was from Packard (Zurich, Swtt- 
zerland). N, K-Dimethylcasein and bovine serum albumin were from 
Fluka (Switzerland). All-rrans RA was from Sigma (St. Louis, MO). 
Cisplatm was from Bristol Labs. (Syracuse, NY). Cell culture media 
and plastic were from Flow (UK). Other chemicals were of reagent 
grade and used without further purification. 
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2.2. Cell cultures 
The parental SK-N-BE(2) line and its clonally derived lines BE(Z)-C 
[I-type] and BE(Z)-Ml 7 [N-type] were grown in a 1: 1 mixture of MEM 
and Hams F-12 media supplemented with 15% (v/v) heat-inactivated 
foetal calf serum, 2 mM L-glutamine, 1.2 g/liter bicarbonate, non- 
essential amino acids (1% v/v) and 15 mM HEPES in humidified 
atmosphere with 5% (v/v) CO, at 37°C. All the experiments were 
performed using the cell lines at 70_76th, 33-37th and 2629th pas- 
sage, respectively. 
Cells were plated at 5 x 10“ cells/cm* in growth medium containing 
5 PM RA (from a 5 mM stock solution dissolved in 70% ethanol) or 
5 PM cisplatin (from a 1.7 mM stock solution dissolved in PBS). 
Medium was replaced daily. Control cultures were treated with 0.07% 
ethanol. Cell number and viability were evaluated in a Thoma 
haemocytomer chamber. The cell cycle was evaluated by flow cy- 
tometry using propidium iodide staining [21] on a FACScan flow 
cytometer (Becton-Dickinson, CA, USA). 
2.3. Biochemical determinations 
Mechanically removed cells, washed m (Ca”‘lMg*‘)-free PBS, were 
sonicated (4°C for 20 s) and tTG activity was measured by detecting 
the incorporation of [‘Hlputrescine into N, N’-dimethylcasein as previ- 
ously reported [25]. The incubation mixture contained 150 mM Tris- 
HCI buffer pH 8.3, 5 mM CaCI,, 10 mM dithiothreitol, 30 mM NaCI, 
2.5 mg N,N’-dimethylcaseinlml, 0.2 mM putrescine (containing 1 PCi 
of [‘Hlputrescine), and 0.14.2 mg of protein in a final volume of 0.3 
ml. After 20 min incubation at 37“C, 100~1 of incubation mixture was 
spotted onto Whatman 3MM filter paper moistened with 20% trichlo- 
roacetic acid (TCA). Free [“Hlputrescine was eliminated by washing 
with large volumes of cold 5% TCA containing 0.2 M KCI; dry filters 
were counted with 8 ml Opti-fluor [18]. Protein concentration was 
determined as previously described using bovme serum albumin as 
standard [25]. 
2.4. Quantification of apoptotic bodies 
Cross-linked apoptotrc bodies were estimated on cells cultured in 
25 cm* flasks, as described [12,25]. Cells floating in the culture medium 
for the previous 24 h were collected by centrifugation at 800 x g for 
5 min and pooled with the cells mechanically recovered from flasks. 
Then the cells, washed in PBS, were spun and suspended in lysis buffer 
(10 mM KCl, 2 mM MgCI,, 0.5% Triton X-100 in 10 mM Trrs-HCl, 
pH 7.5) containing 0.2 mM phenylmethyIsulphony1 fluoride to inhibit 
proteases and 0.4 mM iodoacetamide to inhibit transglutaminase. 
After centrifugation the pellet was washed in the lysis buffer and 
suspended in 6 M guanidine hydrochloride to dissolve nuclei [ 121. The 
pellet from the subsequent centrifugation was suspended in 2% SDS 
solution containing 0.05 mM p-mercaptoethanol, boiled, and the num- 
ber of detergent-insoluble apoptotic bodies was scored using a phase 
contrast microscope (Laborlux D, Leitz). Apoptotic bodies were also 
evaluated by flow cytometry using propidium iodide staining [6,7] on 
a FACScan flow cytometer (Becton-Dickinson, CA, USA). 
3. RESULTS AND DISCUSSION 
We demonstrated that human neuroblastoma cells 
(SK-N-BE(2)) undergo spontaneous apoptosis in cul- 
ture [24], furthermore, we found that RA treatment for 
a few days was able to significantly enhance their cell 
death rate [24]. Apoptosis was associated with a specific 
increase of tTG expression (mRNA, protein and cross- 
linking activity) in the apoptotic cells which was re- 
stricted to neuroblastoma cells showing the S-morphol- 
ogy [261. 
In the present study we have investigated whether 
other agents, beside RA, are able to enhance tTG activ- 
ity and apoptotic index. Particularly, it has recently 
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Fig. 1. (A) Growth mdex of SK-N-BE(Z) human neuroblastoma cells 
and its derivative clones, BE(2)-Ml7 and BE(Z)-C, following 4 h incu- 
bation with 5 PM cisplatin. All 3 cell lines show a drastic reduction 
in growth rate. (B) Cell cycle analysis by flow cytometry of untreated 
(line 1) and cisplatin treated (5 PM for 4 h: line 2) SK-N-BE(2) cells. 
showing a sharp G2/M block induced by cisplatin. (C) Cell volume 
analysis by flow cytometry of untreated (line I) and cisplatin treated 
(5 PM for 4 h; line 2) SK-N-BE(2) cells. Note the increase m cell 
volume in cisplatin treated cells (B; line 2). 
been suggested that chemotherapeutic agents such as 
cisplatin, exert their cytopathic activity by triggering 
apoptosis in malignant cells [l]. Fig. 1A shows that 
cisplatin is able to induce a large growth inhibition in 
SK-N-BE(Z) parental cell line as well as in its neuroblas- 
tic (BE(2)-M17) and substrate-adherent (BE(2)-C) de- 
rived clones. In addition, after 4 h exposure to cisplatin 
the SK-N-BE(2) cells are blocked in G2-M phase of the 
cell cycle (Fig. 1B) and show a significant increase in 
their mean volume (Fig. 1C). Noteworthy, the growth 
inhibition observed in the SK-N-BE(2) parental cell line 
as well as in its derived clones (Fig. 1A) is parallelled by 
a proportional increase in tTG activity (Table I). 
Apoptotic cells do not lyse, but shrink and fragment 
into smaller membrane-limited particles with a charac- 
teristic morphology (apoptotic bodies) [l 1,30,3 11; their 
proteins are extensively cross-linked by tTG which ren- 
151 
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Table I 
Effect of cisplatin on ‘tissue’ transglutaminase activity and His-dependent 
cross-linked apoptotic bodies formation m human neuroblastoma cell 
lines 
Treatments SK-N-BE(Z) BE(2)C BE(2)M17 
wild type Intermediate neuroblastic 
tTG activity* 
None 
Cisplatin (24 h) 
Cisplatin (48 h) 
77+ 11 72f 17 23* IO 
97f 12 128 f 11 70f 13 
107 f 15 158 f 15 75 f 10 
Cross-linked apoptotic envelopes** 
None 0.1 0.3 0.4 
Cisplatin 0.3 2.0 2.5 
Cells were cultured as described in the experimental section in the 
presence of 5 PM cis-platinum for 14 h, after treatment cells were 
extensively washed in RPM1 and then cultured for additional 48 h, 
then after washing in PBS mechanically removed from flasks. 
*In vitro tTG activity was measured as pmol of [‘Hlputrescine 
incorporated into protein/h/mg protein. Data are the mean + S.E.M. 
of triplicate determinations carried out on three different experiments. 
**tTG-dependent formation of detergent-insoluble cross-linked 
apoptotic envelopes was evaluated at the phase microscope as de- 
scribed in section 2. Data are the mean of duplicate determinations 
with an S.E.M. less than 15%. 
ders them resistant to treatment with detergents 
[12,24,25]. The evidence that tTG expressed in the dying 
cells derived from cisplatin-treated SK-N-BE(2) cells is 
Table II 
Effect of caffeine, TGFB, okadaic acid and RA on ‘tissue’ transglu- 
taminase activity in BE(2)-C cells 
tTG activity* 
(pmollh/mg protein) 
Control 782 10 
Caffeine (2 mM) 
6h 705 12 
14 h 35+ 3 
24 h 54f 7 
TGFB (80 PM) 
12 h 30f 5 
24 h 30f 3 
48 h 50+ 3 
Okadaic acid (0.5 PM) 
5h 36+ 6 
16 h 34f 4 
Retinoic acid (5 ,LLM) 
24 h 87+ 16 
48 h 216 + 30 
*In vitro tTG activity was measured as pmol of [3H]putrescine incor- 
porated into protein/h/mg protein. Data are the mean f S.E.M. of 
triplicate determinations carried out on three different experiments. 
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actively cross-linking the intracellular protein is also 
reported in Table I. In fact, the number of the cross- 
linked apoptotic bodies recovered from the cultures 
upon cisplatin-treatment is largely increased (3- to over 
6-fold) and strictly parallels the increased tTG activity. 
The induction of tTG activity upon cisplatin-treatment 
is detectable, even though at lesser specific activity with 
respect o the BE(2)-C clone, also in the ‘N-type’ BE(2)- 
Ml7 clone (Table I). This result is very interesting since 
our previous studies demonstrated that RA was unable 
to induce apoptosis in the neuronal BE(2)-Ml7 cell 
clone [24,26], which instead evidenced a relative resis- 
tance to RA treatment [21]. By contrast, the results 
presented in Table I indicate that the neuronal differen- 
tiation stage reached by this clone can still be forced by 
cisplatin into the programmed eath pathway, thus im- 
plying that the death programme in neuroblastic cells 
is not irreversibly blocked. In addition, Table II indi- 
cates that cisplatin and RA are the only agents tested 
able to enhance the tTG activity; in fact okadaic acid 
and TGFD which have been shown to induce apoptosis 
in other systems [3,11,14], were unable to increase tTG 
activity in our model. 
Several reports suggest hat the ‘priming state’ for 
apoptosis could be related to specific phases of the cell 
cycle, as well as to the differentiation stage [8,25]. In 
order to investigate this point we analysed the cell cycle 
phases of human neuroblastoma SK-N-BE(2) cell upon 
exposure to both RA and cisplatin at different time 
intervals. Table III indicates that, while RA causes the 
accumulation of cells in the G, phase, cisplatin blocks 
Table III 
Effect cisplatin, caffeine and RA on cell cycle phases of BE(2)-C cells 
Treatment G,/G, S Gz /M 
None 63.6 18.4 18.0 
Cisplatin (4 h) 39.4 16.4 44.1 
Cisplatin (36 h) 21.2 21.3 57.5 
Caffeine (6 h) 65.7 14.3 20.1 
Caffeine (12 h) 69.2 14.5 16.0 
Caffeine (24 h) 71.2 17.5 11.1 
Cisplatin (4 h) + caffeine (24 h) 40.0 16.9 42.5 
Cisplatin (36 h) + caffeine (24 h) 21.1 26.4 51.4 
Retinoic acid (72 h) 80.1 9.4 10.3 
Retinoic acid (96 h) 77.0 8.8 14.2 
Retinoic acid (120 h) 79.7 9.8 10.5 
Cisplatin (5 PM) was added for 4 h or 36 h and after extensive washing 
caffeme (2 mM) was added for an additional 6 h or 24 h. RA was 
added at the final concentration of 5 PM for up to 5 days. Cell cycle 
analysis was performed on methanohacethone fixed cells (4:1, at 
-20°C) incubated with 10 pg/ml iodidum propide and 15 kU/ml 
RNase for 30 min at 37°C. Fluorescence at 580 nm was collected on 
a FACScan analyzer and evaluated and 10,000 events using a CellFit 
programme. 
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Fig. 2. 3D-evaluation of cell cycle in SK-N-BE(2) cells; untreated (panel A), and treated with 5 mM caffeine for 12 h (panel B) or 24 h (panel C). 
Cells were also treated with 5 pM cisplatin for 4 h (panel D), followed by 5 mM caffeine for 24 h (panel E) or 48 h (panel F), The axes represent 
580 nm fluorescent emission by propidium iodide (x), cell volume (z), and number of events (y). The three main peaks indicate apoptotic ells (peak 
1), cells m G0/G1 (peak 2) and cells in G2/M (peak 3). Cisplatin induces a sharp arrest in G2/M (panels A, D), and caffeine removes the G2/M 
checkpoint both in untreated cells (panels A-C) and in cisplatin-treated cells (panels D-F). 
the cells in the G2/M phase (see also Fig. 2 panels A and 
D); the percentage of cells accumulated in GJM is de- 
pendent on the exposure time to cisplatin. Since both 
RA and cisplatin kill neuroblastoma cells by triggering 
apoptosis our finding indicate that this programme is
accessible from different cell cycle phases, namely G0/G1 
and G2/M. The transitions through G1/S and GJM are 
regulated by the so-called checkpoints control which are 
surveilled by specific genes [16]. One of the recent most 
exciting developments in cell cycle regulation is that an 
unproper completion of its key events (DNA duplica- 
tion, chromosome segregation and cell cleavage) may 
result in the induction of cell death programme. P53 has 
recently been suggested to play a pivotal role in the 
control of G~/S transition by switching on the apoptosis 
in case the cell has damaged DNA [32]. In this regard 
the occurrence of apoptosis following cisplatin could be 
envisaged as a defence mechanism to eliminate dam- 
aged cells in order to avoid cycling mutated cells under- 
going definitive transformation. In order to investigate 
this hypothesis we attempted to force the GJM block 
ofcisplatin-damaged cells by caffeine. Caffeine is a syn- 
ergistic agent, potentiating slow death by nitrogen mus- 
tard in G2 arrested hamster kidney cells [18]. Caffeine, 
acting as a partially specific protein kinase inhibitor, 
allows cells with damaged or unreplicated DNA to enter 
mitosis, overcoming feedback controls [27]; see the re- 
duction of peak 3 (G2/M) in panels A-C in Fig. 2 and 
Table III. This aberrant mitosis may force the cells to 
death, possibly by inducing apoptosis [18,22]. However, 
we failed to detect apoptosis both by morphological 
(Fig. 2 peak 1 in panels D-F) or biochemical (tTG 
activity and crosslinked apoptotic bodies; data not 
shown) analysis in cells treated with cisplatin followed 
by 2 mM caffeine for 6 to 48 h. Thus, the reported 
potentiation of lethality by caffeine in G2 damaged cells 
in our model occurs by mechanisms other than pro- 
grammed cell death. In keeping with this hypothesis 
Fig. 2 shows the accumulation of small hypochromic 
cells with fragmented chromatin upon exposure to cis- 
platin and subsequently to caffeine for 48 h (peak 1, 
panels D-F). The cells in peak 1 are gated upon scatter 
and fluorescence mission, and previous studies have 
shown that cells presenting these features by FACS 
analysis indeed have their DNA cleaved at the internu- 
cleosomal linker regions [6,17]. In connection with this, 
it is important o mention that the DNA of cells, espe- 
cially when blocked in mitosis, could be cleaved in a 
typical 'ladder' pattern by the DNAI localized in the 
cytoplasm [23] and this phenomenon is independent 
from mRNA and protein synthesis [5]. The data re- 
ported herein show that the effect of caffeine does not 
153 
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require tTG induction, thus suggesting that neuroblas- 
toma cells can also die by alternative pathways which 
only share some features (DNA fragmentation) with the 
physiological gene-dependent programme of cell death. 
The mechanism of action of RA seems to contem- 
plate an arrest of the cells in G, followed by an active 
switch of the neuronal differentiation or apoptotic path- 
way depending on the maturational stage of the neural 
crest derived cell [24,26]. In keeping with this is our 
finding that apoptosis induced by RA is S-phenotype 
specific [24,26]; while both the neuroblastic and the sub- 
strate-adherent cells can be forced to apoptosis by cis- 
platin, which seems to have broader, less specific effects. 
The detailed molecular mechanisms of apoptosis are 
still largely unknown in eukaryotic cells, thus if this 
difference is due to the expression of specific key regula- 
tory genes represents matter for future investigations. 
Although the data presented in this report do not enable 
us to speculate whether RA and cisplatin use the same 
pathway to reach the common end result, however, the 
fact that they share an enhanced expression of one of 
the effector elements of the apoptotic programme (tTG) 
[l 11, might suggest hat RA and cisplatin have two sep- 
arate cell cycle startpoints for a common pathway of 
programmed cell death. In keeping with this it has re- 
cently been reported that, in synchronized cells, tTG 
activity is detectable in all phases of the cell cycle, but 
with a relative peak during mid S-phase [8]. 
In conclusion, the present report demonstrates vari- 
ous chemical agents force human neuroblastoma cells 
to enter the apoptotic death programme from different 
cell cycle phases. These data are in keeping with those 
recently reported in Rat-l fibroblast cells having a de- 
regulated c-myc expression and Al. 1 T-cell hybridoma 
which also enter apoptosis from various points through 
the cell cycle [5,8]. thus further underlying the profound 
connection between apoptosis and cell-cycle regulation 
[2,9,10]. 
Acknowledgemenfs: We would like to thank Professors A. Finazzi- 
Agrb and F. Autuori for helpful discussions and encouragement. This 
work was partially supported by the CNR projects ‘ACRO’ and 
‘BTBS’. and by the Ministry of Health ‘AIDS’ projects. 
REFERENCES 
[1] Barry, M.A., Behnke, C.A. and Eastman, A. (1990) Biochem. 
Pharmacol. 40, 2353-2362. 
[2] Bissonnette, R.P., Echeverri, F., Mahboubi and Green, D.R. 































Boe, R., Gjertsen, B.T., Vintermyr, O.K., Houge, G., Lanotte, 
M. and Doskeland, SO. (1991) Exp. Cell Res. 195, 237-246. 
Ciccarone, V., Spengler, B.A., Meyers, M.B., Biedler, J.L. and 
Ross, R.A. (1989) Cancer Res. 49, 219-225. 
Cotter, T.C., Glynn, J.M., Echeverri, F. and Green, D.R. (1992) 
Anticancer Res. 12, 773-780. 
Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz. 
M.A., Lassota, P. and Traganos, F. (1992) Cytometry 13, 7955 
808. 
Dive, C. and Hickman, J.A. (1991) Br. J. Cancer 64, 192-196. 
El Alaoui, S., Mian, S., Lawry, J., Quash, G. and Griffin, M. 
(1992) FEBS Lett. 311, 174178. 
Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Land, 
H., Brooks, M., Waters, C.M., Penn, L.Z. and Hancock, D.C. 
(1992) Cell 69, 119-128. 
Fanidi, A., Harrington, E.A. and Evan. G.I. (1992) Nature 359, 
554556. 
Fesus, L., Davies, P.J.A. and Piacentini, M. (1991) Eur. J. Cell 
Biol. 56, 170-177. 
Fesus, L.. Thomazy, V., Autuori, F., Ceri, M.P., Tarcsa, E. and 
Piacentini, M. (1989) FEBS Lett. 245, 150-154. 
Folk, J.E. (1980) Annu. Rev. Biochem. 49, 517-531. 
Ishida, Y., Furukawa, Y., Decaprio, J.A., Saito, M. and Griffin, 
J.D. (1992) J. Cell. Physiol. 150, 484492. 
Ghibelli. L., Farrace, M.G., Guerrieri, P.. Melino, G. and Pi- 
acentini, M. (1989) Clin. Chem. Enzymol. Commun. 2,299-307. 
Hartwell, L.H. and Weinert, T.A. (1989) Science 246, 629-634. 
Jones. T.L. and Lafrenz (1992) Cell. Immunol. 142, 3488360. 
Lau, CC. and Pardee, A.B. (1982) Proc. Natl. Acad. Sci. USA 
19, 2942-2946. 
Melino, G., Farrace, M.G., Cerh, M.P. and Piacentini, M. (1988) 
Exp. Cell Res. 179, 42945. 
Melino, G., Knight, R.A. and Thiele, C.J. (1993) Cancer Res. 53, 
l-3. 
Melino, G., Stephanou, S., Annicchiarico-Petruzzelli, M., 
Knight, R.A., Finazzi-Agro, A. and Lightman. S.L. (1993) Neu- 
rosci. Lett. 148. 
Murray. A.W. (1992) Nature 359, 5999604. 
Peitsch, M.C., Hesterkamp, T., Polzar, B., Mannherz, H.G. and 
Tschopp, J. (1992) Biochem. Biophys. Res. Commun. 186, 739- 
745. 
Piacentini, M., Fesus, L., Farrace, M.G., Ghibelli, L., Piredda. 
L. and Melino, G. (1991) Eur. J. Cell Biol. 54, 246254. 
Piacentini. M., Autuori, F., Dini, L.. Farrace, M.G.. Ghibelli, L., 
Piredda. L. and Fesus, L. (1991) Cell Tissue Res. 263, 227-235 
Piacentini, M., Annicchiarico-Petruzzelli, M., Oliverio, S., 
Piredda, L., Biedler, J.L. and Melino, G. (1992) Int. J. Cancer 52, 
271-278. 
Schlegel, R. and Pardee, A.B. (1986) Science 232, 12641266. 
Sorenson. C.M., Barry, M.A. and Eastman, A. (1990) J. Natl. 
Cancer Inst. 82, 749-755. 
Thomazy, V. and Fesus. L. (1989) Cell Tissue Res. 255,215-224. 
Wyllie, A.H. (1987) J. Pathol. 153. 313-316. 
Wyllie, A.H., Kerr, J.F.R. and Currie, A.R. (1980) Int. Rev. 
Cytol. 68. 251-306. 
Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L.. Kimchi, 
A. and Oren, M. (1991) Nature 352, 345-347. 
154 
